Integrated Wealth Concepts LLC Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Integrated Wealth Concepts LLC cut its Regeneron position by 45.3% in the second quarter, selling 1,902 shares and retaining 2,299 shares valued at approximately $1.43 million. Institutional investors still own 83.31% of the company.
• Analysts maintain a “Moderate Buy” consensus on REGN, with 14 Buy ratings and 10 Holds and an average price target of $802.18.
• Regeneron exceeded quarterly expectations, reporting $14.29 in EPS and $4.29 billion in revenue, while revenue increased 16.7% year over year. The company also pays a quarterly dividend of $0.94 per share, yielding approximately 0.5%.

Integrated Wealth Concepts LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 45.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,299 shares of the biopharmaceutical company's stock after selling 1,902 shares during the period. Integrated Wealth Concepts LLC's holdings in Regeneron Pharmaceuticals were worth $1,433,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $5,682,636,000. Franklin Resources Inc. lifted its position in shares of Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company's stock valued at $1,975,990,000 after buying an additional 106,861 shares in the last quarter. Nuveen LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock valued at $1,551,858,000 after buying an additional 835,240 shares in the last quarter. Invesco Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 7.2% during the 4th quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company's stock valued at $1,228,127,000 after acquiring an additional 106,632 shares during the period. Finally, Norges Bank bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $1,012,296,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on REGN. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 12th. Citigroup increased their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a research note on Monday, August 3rd. Cantor Fitzgerald raised their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Finally, Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating on the stock in a research report on Thursday, July 9th. Fourteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $802.18.

Regeneron Pharmaceuticals Stock Up 0.1%

NASDAQ REGN opened at $774.61 on Thursday. The stock's 50 day moving average is $762.00 and its 200 day moving average is $720.22. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $859.34. The stock has a market cap of $79.75 billion, a PE ratio of 19.15, a P/E/G ratio of 1.52 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company's revenue was up 16.7% on a year-over-year basis. During the same period last year, the firm posted $12.81 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares of the company's stock, valued at $11,163,900. This represents a 8.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director directly owned 603 shares of the company's stock, valued at $512,550. This trade represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 4,146 shares of company stock valued at $3,432,488. Insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.